Volume 27, No 8, Aug 2017

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 27 Issue 8, August 2017: 963-964

RESEARCH HIGHLIGHTS

Repolarizing macrophages improves breast cancer therapy

Luca Cassetta1 and Jeffrey W Pollard^1,2

¹MRC Centre for Reproductive Health, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK
²Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, New York 10461, USA Correspondence: Jeffrey W Pollard,(Jeff.Pollard@ed.ac.uk)

Tumor-associated macrophages (TAMs) contribute to breast cancer progression and dissemination; TAM-targeting strategies aimed at their reprogramming show promising preclinical results. In a new report Guerriero and colleagues demonstrate that a novel HDAC Class IIa inhibitor, TMP195, can reprogram monocytes and macrophages in the tumor into cells able to sustain a robust CD8 T cell-mediated anti-tumoral immune response.

10.1038/cr.2017.63

FULL TEXT | PDF

Browse 1821